These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11693321)

  • 1. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study.
    van Grieken NC; Meijer GA; Weiss MM; Bloemena E; Lindeman J; Baak JP; Meuwissen SG; Kuipers EJ
    Am J Gastroenterol; 2001 Oct; 96(10):2882-6. PubMed ID: 11693321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after Helicobacter pylori eradication.
    van Grieken NC; Meijer GA; Kale I; Bloemena E; Lindeman J; Offerhaus GJ; Meuwissen SG; Baak JP; Kuipers EJ
    Digestion; 2004; 69(1):27-33. PubMed ID: 14755150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.
    Koskenpato J; Farkkilä M; Sipponen P
    Am J Gastroenterol; 2001 Oct; 96(10):2866-72. PubMed ID: 11693319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study.
    Demiray M; Gulten M; Manavoglu O; Evrensel T; Ulukaya E; Yerci O; Kanat O; Kurt E; Arslan M; Gonullu G; Demiray H; Gulten T; Memik F
    Hepatogastroenterology; 2004; 51(59):1531-5. PubMed ID: 15362794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
    Lundell L; Havu N; Miettinen P; Myrvold HE; Wallin L; Julkunen R; Levander K; Hatlebakk JG; Liedman B; Lamm M; Malm A; Walan A;
    Aliment Pharmacol Ther; 2006 Mar; 23(5):639-47. PubMed ID: 16480403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
    Bergman MP; Klinkenberg-Knol EC; Faller G; Aar A; Lakhai W; Vandenbroucke-Grauls CM; Kuipers EJ; Appelmelk BJ
    Aliment Pharmacol Ther; 2005 Apr; 21(8):977-83. PubMed ID: 15813833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication.
    Zhou L; Sung JJ; Lin S; Jin Z; Ding S; Huang X; Xia Z; Guo H; Liu J; Chao W
    Chin Med J (Engl); 2003 Jan; 116(1):11-4. PubMed ID: 12667379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.
    Koskenpato J; Färkkilä M; Sipponen P
    Scand J Gastroenterol; 2002 Jul; 37(7):778-84. PubMed ID: 12190090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gastric mucosa lesions in gastric ulcer disease. Initial study and 1-year follow-up after Helicobacter pylori eradication].
    Bermejo F; Boixeda D; Gisbert JP; Sanz JM; Defarges V; Alvarez Calatayud G; Martín de Argila C
    Gastroenterol Hepatol; 2000; 23(6):269-74. PubMed ID: 15324621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effects of eradication therapy in patients with chronic atrophic gastritis and seropositivity for anti-HP antibodies and histological negativity for Helicobacter pylori].
    Leri O; Mastropasqua M; Scopelliti G; Grasso E; Losi T; Iadicicco A; Perinelli P
    Clin Ter; 1999; 150(5):343-6. PubMed ID: 10687264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of fundic atrophy after eradication of Helicobacter pylori.
    Tucci A; Poli L; Tosetti C; Biasco G; Grigioni W; Varoli O; Mazzoni C; Paparo GF; Stanghellini V; Caletti G
    Am J Gastroenterol; 1998 Sep; 93(9):1425-31. PubMed ID: 9732919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study.
    Arkkila PE; Seppälä K; Färkkilä MA; Veijola L; Sipponen P
    Scand J Gastroenterol; 2006 Jul; 41(7):782-90. PubMed ID: 16785190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of corpus gastritis, atrophy and cyclooxygenase in the development of gastric erosions after curing Helicobacter pylori infection.
    Miyake K; Tatsuguchi A; Suzuki K; Ueki N; Shinji Y; Kusunoki M; Iizumi T; Hiratsuka T; Nishigaki H; Futagami S; Wada K; Tsukui T; Sakamoto C
    Dig Liver Dis; 2005 Jun; 37(6):394-401. PubMed ID: 15893277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
    Kowalski M
    J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
    Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
    Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term course of reflux symptoms following Helicobacter pylori eradication].
    Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P
    Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Helicobacter pylori eradication and antisecretory maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study.
    Tzathas C; Triantafyllou K; Mallas E; Triantafyllou G; Ladas SD
    J Clin Gastroenterol; 2008 Jul; 42(6):744-9. PubMed ID: 18277886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori eradication decreases the expression of glycosylphosphatidylinositol-anchored complement regulators, decay-accelerating factor and homologous restriction factor 20, in human gastric epithelium.
    Joh T; Sasaki M; Kataoka H; Tanida S; Itoh K; Kondo Y; Ogasawara N; Oshima T; Okada N; Ohara H; Sano H; Nakao H; Sobue S; Itoh M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1344-51. PubMed ID: 16105119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.